✦ LIBER ✦

Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

✍ Scribed by Stephen Palmer; Mark Sculpher; Zoe Philips; Mike Robinson; Laura Ginnelly; Ameet Bakhai; Keith Abrams; Nicola Cooper; Chris Packham; Khaled Alfakih; Alistair Hall; David Gray

Book ID: 116543537
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 337 KB
Volume: 100
Category: Article
ISSN: 0167-5273
DOI: 10.1016/j.ijcard.2004.08.042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of bivalirudin versus

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes

✍ Matthias Schwenkglenks; John E. Brazier; Thomas D. Szucs; Keith A.A. Fox 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 985 KB

The emerging role of platelet glycoprote

The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes

✍ Bolognese, Leonardo 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 366 KB

EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBIT

EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL

✍ Cornel, J.H.; Tricoci, Pierluigi; Horton, john; Moliterno, David; Wallentin, Lar 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 146 KB